Overcoming gaps in the management of chronic obstructive pulmonary disease in older patients: new insights.
Chronic obstructive pulmonary disease (COPD) is a common disorder with a high prevalence among elderly men and women and an increasing mortality rate. Its diagnosis relies on spirometry, with a diagnostic cut-off value of a forced expiratory volume in 1 second (FEV(1))/forced vital capacity ratio of <0.7. This cut-off level has received some criticism because a ratio decline is part of normal advanced aging. Thus, clinicians must be vigilant in applying appropriate diagnostic criteria when managing elderly patients and may choose to use one or more of the alternative diagnostic values that have been created. It is important to remember that COPD is a systemic disorder with several extrapulmonary manifestations. Elderly patients with COPD are at an increased risk of cardiovascular events, osteoporosis, fractures, peripheral muscle wasting, depression and anxiety. Management of these patients requires a multidisciplinary approach and should begin with stratification of disease severity and prognostic information for each patient. Traditionally, FEV(1) has been used as a marker of COPD severity. However, indices such as the Modified Medical Research Council (MMRC) Dyspnoea Scale; the updated body mass, airflow, obstruction, dyspnoea and exercise (BODE) index; and the new age, dyspnoea, obstruction (ADO) index have been found to be better predictors of mortality in elderly patients. In addition to smoking cessation, supplemental oxygen and vaccines, management strategies such as patient education programmes--which have been shown to reduce hospital admissions--should not be overlooked. Pulmonary rehabilitation remains an underutilized treatment modality despite its demonstrated association with improvements in quality of life, reduced dyspnoea and increased exercise capacity. Studies have shown no correlation between age and outcomes in pulmonary rehabilitation, suggesting that age should not be an exclusion criterion. Although bronchodilators and corticosteroids remain the cornerstone of pharmaceutical management of COPD, their efficacy relies on correct medication administration. Inhaler technique should be frequently assessed in the elderly population and the choice of inhaler device needs to be tailored to the patients' needs, situation and preferences. Assessment and management of extrapulmonary co-morbidities of COPD should also be undertaken. Careful attention to the mental health of elderly patients with COPD is also vital, as they have high rates of depression and anxiety. Furthermore, elderly patients with severe COPD receive inadequate palliative care despite the elevated mortality risk associated with this illness. Early discussion about end-of-life care and advanced care planning is recommended.
Gelberg
Jacob
J
Department of Internal Medicine, Queens University, Kingston, Ontario, Canada.
McIvor
R Andrew
RA
D000368:Aged; D015897:Comorbidity; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy*; D013727:Terminal Care
J Pain Symptom Manage. 2006 Jan;31(1):58-69
16442483
BMJ. 2001 Jul 7;323(7303):49-50
11464828
Eur Respir J. 1996 Mar;9(3):431-5
8730000
Age Ageing. 1988 Jul;17(4):275-8
3177088
Psychosomatics. 2007 Jan-Feb;48(1):16-21
17209145
Lancet. 2009 Aug 29;374(9691):667-8
19716945
Chest. 1985 Jan;87(1):35-8
3965263
J Cardiopulm Rehabil. 2001 Jan-Feb;21(1):10-7
11271652
Chest. 2008 Oct;134(4 Suppl):43S-56S
18842932
Age Ageing. 2008 Sep;37(5):530-5
18565981
Can Fam Physician. 2008 May;54(5):706-11
18474704
Thorax. 1991 Oct;46(10):695-9
1750015
Can Respir J. 2004 Sep;11(6):407-13
15510248
Thorax. 2008 Dec;63(12):1046-51
18786983
Chest. 2005 Apr;127(4):1205-11
15821196
Am J Respir Crit Care Med. 2005 Jul 1;172(1):19-38
15778487
Chest. 2005 Oct;128(4):2068-75
16236856
Chest. 1988 Mar;93(3):580-6
3342669
Can Respir J. 2008 Jan-Feb;15(1):13-9
18292848
Osteoporos Int. 2010 Aug;21(8):1341-9
19816753
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
12091180
Pharmacoepidemiol Drug Saf. 1996 May;5(3):155-64
15073832
Can Respir J. 2009 Sep-Oct;16(5):e51-3
19851529
Eur Respir J. 1996 Nov;9(11):2346-50
8947083
N Engl J Med. 2007 Feb 22;356(8):775-89
17314337
Chest. 2005 Jun;127(6):2188-96
15947336
Am J Respir Crit Care Med. 2006 Jan 1;173(1):79-83
16368793
Age Ageing. 2004 Nov;33(6):548-55
15385272
Chest. 2002 May;121(5):1434-40
12006425
Chest. 2005 Oct;128(4):2099-107
16236861
Ann Phys Rehabil Med. 2010 Mar;53(2):69-76
20018583
Chest. 2009 Dec;136(6):1456-1465
19581353
N Engl J Med. 2004 Mar 4;350(10):1005-12
14999112
Can Respir J. 2008 Jan-Feb;15 Suppl A:1A-8A
18292855
Eur Respir J. 2006 Dec;28(6):1245-57
17138679
Arch Intern Med. 2003 Mar 10;163(5):585-91
12622605
Am Rev Respir Dis. 1989 Jun;139(6):1435-8
2658702
Eur Respir J. 2008 Sep;32(3):796-803
17989116
Arch Intern Med. 2007 Nov 26;167(21):2345-53
18039994
Can Fam Physician. 2008 May;54(5):737-9
18474708
Am J Respir Crit Care Med. 1999 Dec;160(6):1856-61
10588597
Eur Respir J. 2009 Sep;34(3):588-97
19460786
Eur Respir J Suppl. 2003 Nov;46:52s-63s
14621107
Chest. 2005 Jan;127(1):328-34
15654000
Drugs Aging. 1993 Jul-Aug;3(4):335-48
8369593
Eur Respir J. 1997 Dec;10(12):2801-6
9493664
Age Ageing. 2007 Mar;36(2):213-8
17267450
Am J Respir Crit Care Med. 1998 Aug;158(2):629-34
9700144
Acta Biomed. 2007 Dec;78(3):233-45
18330086
Am J Med. 2003 Jan;114(1):10-4
12543283
Psychosomatics. 2006 Jul-Aug;47(4):312-9
16844889
Can Respir J. 2007 Mar;14(2):87-92
17372635
Eur Respir J. 2002 Nov;20(5):1117-22
12449163
Lancet. 2009 Aug 29;374(9691):704-11
19716962